Harbin Cihang Pharmaceutical

Harbin Cihang Pharmaceutical is a comprehensive pharmaceutical enterprise based in Harbin, China, that integrates drug research, development, production, and sales. The company maintains a diverse portfolio encompassing Traditional Chinese Medicine (TCM), chemical drugs, and health supplements, with a core focus on cardiovascular, cerebrovascular, and respiratory health. Its flagship products include Compound Liquorice Oral Solution and Ginkgo Biloba Extract, which are manufactured in its modern, GMP-certified facilities. Harbin Cihang is publicly traded on the National Equities Exchange and Quotations (NEEQ) under the symbol 835535. The company is dedicated to advancing healthcare through the modernization of traditional therapies and the expansion of its chemical pharmaceutical pipeline.